Cytokinetics Inc (NAS:CYTK)
$ 48.15 -0.83 (-1.69%) Market Cap: 5.06 Bil Enterprise Value: 5.27 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Q2 2019 Cytokinetics Inc Earnings Call Transcript

Aug 08, 2019 / 08:30PM GMT
Release Date Price: $13.63 (+2.02%)
Operator

Good afternoon and welcome, ladies and gentlemen, to the Cytokinetics Second Quarter 2019 Conference Call. At this time, I would like to inform you that this call is being recorded. (Operator Instructions)

I will now turn the call over to Diane Weiser, Cytokinetics' Vice President of Corporate Communications and Investor Relations. Please go ahead.

Diane Weiser
Cytokinetics, Incorporated - VP of IR & Corporate Communications

Good afternoon, everyone and thank you for joining us today.

Robert Blum, our President and Chief Executive Officer, will kick off the call with introductory comments about the current state of our business. Then Fady Malik, our EVP of Research and Development, will provide updates on our cardiovascular program, including the Phase III development of omecamtiv mecarbil, our cardiac myosin activator, and the Phase I development of AMG 594, our cardiac troponin activator, both under our collaboration with Amgen as well as the development of CK-274, our wholly owned cardiac myosin inhibitor now proceeding from Phase I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot